Findings

What do systematic reviews say?

6 questions · 8 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 75%High 2 · 25%

Irinotecan vs non‐irinotecan‐containing regimens

Progression‐free survival · people with advanced gastric cancer

Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.76 [0.69, 0.84]
7 studies · 1640 participants
High

Irinotecan vs non‐irinotecan‐containing regimens

Progression‐free survival (PSF) · people with advanced gastric cancer

Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).

3 findings from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.85 [0.72, 1]
5 studies · 741 participants
Moderate
Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.51 [0.33, 0.77]
1 study · 90 participants
Moderate
Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.74 [0.66, 0.84]
2 studies · 809 participants
High

Irinotecan + oxaliplatin vs irinotecan

Progression‐free survival · people with metastatic CRC

Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.6 [0.55, 0.66]
1 study · 627 participants
Moderate

Irinotecan‐based regimens vs irinotecan

Progression‐free survival · people with metastatic CRC

Irinotecan‐based regimens probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.68 [0.6, 0.76]
6 studies · 2615 participants
Moderate

Irinotecan + targeted therapy vs irinotecan

Progression‐free survival · people with metastatic CRC

Irinotecan + targeted therapy probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.71 [0.64, 0.79]
2 studies · 1758 participants
Moderate

IRI with fluoropyrimidines vs single agent IRI

Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer

IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).

1 finding from 1 review

Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
HR 0.68 [0.53, 0.83]
3 studies · 600 participants
Moderate